Bio-rad Laboratories Stock News

According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market. The report gives a guide to the flow cytometry market which will be shaping and changing our lives over the next ten years and beyond, including the market''s response to the challenge of the global pandemic Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market.